Selzentry Related Published Studies
Well-designed clinical trials related to Selzentry (Maraviroc)
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in
the treatment of patients with rheumatoid arthritis in a randomized, double-blind
placebo-controlled trial. [2012]
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. [2011.05]
Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. [2011.01]
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. [2010.10.06]
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. [2010.05]
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. [2010.03.15]
Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. [2010.02.01]
Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. [2010.02]
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. [2010]
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for
the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. [2010]
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. [2009.06.01]
Maraviroc for previously treated patients with R5 HIV-1 infection. [2008.10.02]
Maraviroc: integration of a new antiretroviral drug class into clinical practice. [2008.06]
Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. [2008.04]
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. [2008.04]
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. [2008.04]
A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. [2006.06]
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. [2006.05]
Other research related to Selzentry (Maraviroc)
Interactions between alcohol and the HIV entry inhibitor Maraviroc. [2013]
No effect of a single supratherapeutic dose of lersivirine, a next-generation
nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in
healthy subjects. [2012]
Drug safety evaluation of maraviroc for the treatment of HIV infection. [2011.11.26]
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. [2011.10]
Lessons from maraviroc clinical trials. [2011.06]
A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. [2011.05.10]
Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. [2011.04]
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. [2011.02]
Discordance rates between Trofile test and short-term virological response to maraviroc. [2011.02]
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. [2011.02]
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. [2011.01.15]
Clinical utility of maraviroc. [2011]
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. [2011]
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. [2010.12.21]
Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. [2010.12]
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. [2010.12]
Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico. [2010.12]
Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations. [2010.12]
Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. [2010.12]
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. [2010.09.01]
Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2. [2010.08.11]
CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. [2010.08.01]
Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations. [2010.08]
Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice. [2010.06.28]
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. [2010.06.18]
Treatment of HIV infection with the CCR5 antagonist maraviroc. [2010.05]
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. [2010.05]
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. [2010.05]
A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. [2010.03]
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. [2010.02]
Impact of baseline antiretroviral resistance status on efficacy outcomes among
patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1
and 2 trials. [2010]
Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. [2010]
A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. [2009.10.01]
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. [2009.10]
Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. [2009.10]
Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. [2009.09.10]
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. [2009.09]
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. [2009.08.15]
Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. [2009.06]
Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. [2009.04.15]
Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. [2009.03]
Maraviroc: a new CCR5 antagonist. [2009.02]
Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. [2009]
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. [2008.10.02]
Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). [2008.10]
[Conclusions and perspectives. Maraviroc] [2008.10]
[At what time and with which combinations should maraviroc be indicated in the new antiretroviral treatment scenario?] [2008.10]
[Mechanisms of resistance and failure of treatment with maraviroc] [2008.10]
[Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker] [2008.10]
[Maraviroc efficacy in clinical studies on the development of the molecule] [2008.10]
[Pharmacokinetics, interactions and mechanism of action of maraviroc] [2008.10]
Maraviroc, risks and benefits: a review of the clinical literature. [2008.09]
Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. [2008.07.15]
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. [2008.07]
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. [2008.04]
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. [2008.04]
Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person. [2008.01]
Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV. [2008]
Maraviroc. [2007.11]
Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. [2007.08]
Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A. [2007]
Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. [2007]
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. [2005.11]
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. [2005.11]
Other possibly related research studies
Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. [2008.07]
Complexity of interactions between voriconazole and antiretroviral agents. [2008.05]
Antiviral drugs in the treatment of AIDS: what is in the pipeline ? [2007.10.15]
Genotypic coreceptor analysis. [2007.10.15]
Treatment with CCR5 antagonists: which patient may have a benefit? [2007.10.15]
How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection. [2007.10.15]
CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1. [2007.10.15]
CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1. [2007.10.15]
CCR5 Antagonists: Comparison of Efficacy, Side Effects, Pharmacokinetics and Interactions - Review of the Literature. [2007.10.15]
Antiretroviral treatment of HIV infection: Swedish recommendations 2007. [2007]
Advances in antiretroviral therapy. [2007.04]
Access denied? The status of co-receptor inhibition to counter HIV entry. [2007.05]
Gateways to clinical trials. [2007.01]
The latest in antiretroviral therapy. [2006.10]
The clinical pharmacology of antiretrovirals in development. [2006.06]
Gateways to clinical trials. [2006.05]
CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. [2005]
Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies? [2005.09]
Gateways to clinical trials. [2005.06]
|